Full-Time

Director – Quality Control

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Compensation Overview

$204k - $255k/yr

Expert

San Carlos, CA, USA

This position is hybrid, requiring some in-office presence at the headquarters in Redwood City, CA.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • BS or MS in Chemistry, Pharmaceutical Science or related discipline.
  • 10+ years of relevant industrial experience in analytical development/QC.
  • Solid understanding of relevant compliance and regulatory requirements as applicable to data integrity, process validation, manufacture sampling and testing, stability study, method validation and transfer, etc.
  • Effective written and verbal communication skills and interpersonal skills.
  • Extensive knowledge and understanding of cGMP guidelines and practices, as well as related / best industry practices.
  • Strong problem-solving skills with sound technically driven decision-making ability.
  • Excellent communication skills (verbal, written and technical), strong interpersonal/collaboration skills and planning skills.
  • Ability to think critically and creatively and be able to work independently to determine appropriate resources for resolution of problems.
  • Ability to multi-task and thrive in a fast-paced innovative environment.
Responsibilities
  • Playing a project leading role and Subject Matter Expert (SME) of late phase and commercial Quality Control within in Quality Control within the CMC function.
  • Overseeing a team and individually contributing to the management of QC activities from process validation to commercial launch readiness supports of drug substance (DS), drug product (DP) and final product (FP) manufacturing.
  • Provide strategic and tactical ownership for QC activities of late phase and commercial programs, including but not limited to commercial launch readiness including establishment of CDMO and/or CTL.
  • End to end process management for analytical purposes in support of manufacturing operations for release of commercial product.
  • Oversee and manage outsourced commercial QC activities at CDMOs and/or contract testing labs (CTLs) for release and stability purposes.
  • Manage quality events related to commercial QC testing such as lab investigation (e.g., OOS/OOT), deviations, change controls (e.g., CBE 30/CBE 0) and CAPAs.
  • Support regulatory submissions and commercial life cycle management to maintain operational uniformity.
  • Collaborate with cross functional teams including CMC RA, DS, DP, Supply Chain and Quality Assurance to achieve project goals per timelines.
Desired Qualifications
  • Experience in solid oral dosage including dissolution testing.
  • Work experience and knowledge of global regulatory submissions (IND, IMPD, NDA and MAA, etc.) is preferred.
  • Commercial QC experience.
  • Chromatographic experience in development, optimization, and troubleshooting.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a unique Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to improve cancer treatment outcomes for patients with RAS mutations by providing effective targeted therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital, boosting financial stability.
  • $600M public stock offering shows strong investor confidence and funding for projects.
  • Recognition by the Lustgarten Foundation enhances their reputation in oncology.

What critics are saying

  • EQRx acquisition may lead to integration challenges and cultural clashes.
  • $600M stock offering could dilute existing shareholder value, causing dissatisfaction.
  • Focus on RAS-addicted cancers limits market scope and risks competition.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural product analogues.
  • Their Tri Complex Inhibitor platform targets RAS proteins, a critical cancer growth driver.
  • Exclusive licensing with the University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

7%
PRWeb
May 9th, 2025
The Lustgarten Foundation Honors Revolution Medicines For Transformative Research In Pancreatic Cancer

"Revolution Medicines exemplifies the power of bold science and collaboration in driving meaningful progress for patients," said Linda Tantawi, CEO of the Lustgarten Foundation

Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders